semaglutide biomarkers alzheimer Efficacy and safety of oral 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials Investigating the effects of semaglutide
Description
& Wiktorowicz, K

[DOI] [PMC free article] [PubMed] [Google Scholar] [121].Lisco G, De Tullio A, Disoteo O, et al

Bioessays (2019) 41:e1900046
Based on the current prescribing information, adults in the Wegovy tablet study lost an average of 13.6% of body weight at 64 weeks
